Revenue
No reported data
Medicenna Therapeutics Corp. (MDNAF)
Price—Loading quote
Net income
2020
2021
2022
2023
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
Financial statements
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Research & development | $9.3M | $14.7M | $10.9M | $5.9M |
| Operating expenses | $16.3M | $22.5M | $17.4M | $8.2M |
| Net income | −$10.0M | −$22.6M | −$17.3M | −$8.3M |
| Basic EPSper diluted share | -CA$0.16 | -CA$0.42 | -CA$0.35 | -CA$0.26 |
| Diluted EPSper diluted share | — | — | -CA$0.35 | -CA$0.26 |